Q: What is pharmacovigilance (PV) and why is it critical for pharmaceutical regulatory compliance?
A: Pharmacovigilance is the science and set of regulatory activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. It is mandated by EMA, FDA, CDSCO, MHRA, and virtually all global health authorities. Non-compliance can result in marketing authorization suspension, financial penalties, and serious reputational damage. A well-implemented PV system safeguards patient safety throughout a product’s commercial lifecycle and is central to any MAH’s regulatory obligations.
Q: What is a Pharmacovigilance System Master File (PSMF) and who must maintain one?
A: A PSMF is a detailed description of the pharmacovigilance system used by a Marketing Authorization Holder (MAH). It is mandatory in the EU under Directive 2001/83/EC and GVP Module II. Any MAH holding EU marketing authorizations must maintain a current PSMF at the QPPV’s principal place of work and make it available to competent authorities within 7 calendar days upon request. It must reflect the actual PV system in operation and be updated with any significant changes.
Q: What is the role of a Qualified Person Responsible for Pharmacovigilance (QPPV)?
A: The QPPV is a mandatory EU/UK regulatory requirement for all MAHs. They serve as the single point of contact with regulatory authorities on all PV matters, oversee the pharmacovigilance system, ensure compliance with submission timelines, and maintain overall responsibility for the PSMF and signal management processes. The QPPV must reside and operate within the EU (for EMA) or UK (for MHRA post-Brexit). An absent or under-qualified QPPV is a frequent critical inspection finding.
Q: What are PBRERs and how do they differ from PSURs?
A: A PBRER (Periodic Benefit-Risk Evaluation Report) is the ICH E2C(R2)-aligned successor to the PSUR. While PSURs were primarily safety-focused, PBRERs provide comprehensive benefit-risk analysis across the product lifecycle. The EU requires PBRERs under GVP Module VII; FDA accepts them under certain conditions. Both must be submitted at defined data lock points aligned to the European Reference Date (EURD) list for EU submissions.
Q: What is signal detection and which methods are accepted by regulators?
A: Signal detection involves the systematic analysis of pharmacovigilance data to identify new or changing safety signals. Accepted methods include quantitative disproportionality analysis (PRR, ROR, EBGM) applied to EudraVigilance and FAERS datasets, as well as qualitative case review, clinical data analysis, and literature findings. Companies must document their signal detection methodology in the PSMF and follow GVP Module IX. Identified signals must be formally assessed, prioritized, and tracked through to regulatory action where warranted.
Q: How does literature monitoring support pharmacovigilance compliance?
A: Systematic literature monitoring is mandatory under GVP Module VI. It requires regular, documented searching of medical and scientific databases for potential ADRs not captured via spontaneous reporting. Valid ICSRs identified must be submitted to EudraVigilance within 15 days (serious) or 90 days (non-serious). MAHs often outsource literature monitoring to specialist providers but retain full regulatory accountability. Coverage, search strategies, and screening records must be audit-ready.
Q: What are the ICSR submission timelines to EMA and FDA?
A: For the EMA: Serious unexpected ADRs – 15 calendar days from initial receipt. Serious expected ADRs – 15 days to EudraVigilance. Non-serious cases – 90 days. For the FDA (MedWatch/FAERS): Serious unexpected – 15-day expedited reports. Periodic reporting – quarterly for the first 3 years post-approval, then annually. The ‘clock’ starts when the MAH (or its affiliate/partner) first receives the four minimum ICSR criteria: identifiable patient, reporter, suspect product, and adverse event.
Comments are closed